BMS’ Sprycel Is Latest CDF Drug To Get NICE Clearance For Routine NHS Use
NICE has given the go-ahead for routine NHS commissioning of seven cancer drugs/indications that were listed on the Cancer Drugs Fund before it was overhauled earlier this year. A total of 35 product indications are up for reappraisal under the program.
You may also be interested in...
UK’s NICE Reverses View On Afinitor In Renal Cancer After Novartis Cuts Price
UK HTA body NICE says it is now backing Novartis’s Afinitor for the treatment of some people with advanced kidney cancer on the publicly funded National Health Service after the Swiss group offered a price discount. This changes the availability in England and Wales of the drug, which was previously only available through the controversial Cancer Drugs Fund. NICE has now given the go-ahead for routine commissioning of 13 cancer drugs/indications that were listed on the CDF before it was revamped last year.
UK Cancer Drugs Fund Debuts To Muted Applause From Pharma, Charities
The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.
European Parliament Wants EU-Wide Pull Incentive Scheme For New Antimicrobials
The three major EU institutions are all calling for urgent action to tackle antimicrobial resistance, with the emphasis very much on incentives for the development of novel medicines and a reduction in overall consumption of antibiotics.